In a significant move to strengthen oncological healthcare in Brazil, MGI Tech Co., Ltd. has established a strategic partnership with Oncoclinicas&Co through OC Medicina de Precisão. The collaboration aims to revolutionize cancer diagnostics by expanding access to state-of-the-art genomic testing technologies across the country.
Rising Cancer Burden in Brazil
The partnership comes at a critical time as Brazil faces growing challenges in cancer management. A comprehensive 19-year study by the Federal University of São Paulo (UNIFESP), published in The Lancet Regional Health – Americas, revealed that cancer-related deaths have now exceeded cardiovascular mortality in 727 Brazilian municipalities. This shifting disease burden underscores the urgent need for enhanced diagnostic capabilities and treatment monitoring solutions.
Advancing Precision Medicine Through Technology
The partnership focuses on implementing technological solutions that will transform cancer care delivery. Carlos Carpio, Senior Commercial Director for MGI Latin America and General Manager for Brazil, emphasized the transformative potential of genomics in oncology: "This partnership is a major milestone for oncology in Brazil because it helps raise awareness among patients and professionals about the positive impact of oncogenetics on health promotion, possibilities and benefits of a more precise and personalized medicine."
Enhanced Laboratory Capabilities
The collaboration is set to significantly upgrade laboratory operations at OC Medicina de Precisão, which encompasses Genomics, Pathology, and Big Data laboratories. Fernanda Koyama, Manager of Genomics and R&D at OC Medicina de Precisão, highlighted the operational benefits: "By leveraging cutting-edge technology and expert support, our laboratory can significantly enhance productivity, reduce operational costs, and generate higher-quality data."
Impact on Patient Care
The partnership is expected to deliver multiple benefits to cancer care in Brazil:
- Faster diagnostic processes
- More accurate therapeutic decisions
- Reduced costs for genomic testing
- Improved access to advanced diagnostic technologies
- Enhanced quality of genomic data analysis
This collaborative initiative represents a significant step forward in democratizing access to precision medicine in oncology, potentially improving outcomes for cancer patients across Brazil through more targeted and personalized treatment approaches.
